Journal of Inflammation-London

Journal of Inflammation is an open access journal published by BioMed Central since 2004 and affiliated with the British Inflammation Research Association, covering the full spectrum of inflammation research, with a 2025 Journal Impact Factor of 5.8.《炎症杂志》（Journal of Inflammation）由（BioMed Central）自 2004 年起出版，为开放获取期刊，隶属于英国炎症研究协会，覆盖炎症研究的完整谱系，2025 年期刊影响因子为 5.8。

Scope

• Molecular and cellular mechanisms of acute and chronic inflammation are the journal's central subject.急性与慢性炎症的分子与细胞机制，是期刊的核心主题。
• Mediators, cytokines, reactive oxygen and carbonyl species, and the active resolution of inflammation are treated as connected problems rather than separate topics.炎症介质、细胞因子、活性氧与羰基化物，以及炎症的主动消退，被视为相互关联的问题而非彼此孤立的主题。
• Animal models of inflammatory disease are published alongside human translational studies, provided the relevance to human disease is argued.炎症疾病的动物模型与人体转化研究并列发表，但须论证与人类疾病的相关性。
• The pharmacology of anti-inflammatory drugs, including experimental therapeutics and clinical trials of novel agents, is a long-standing strength.抗炎药物的药理学，包括实验性治疗与新型药物的临床试验，是期刊长期的强项。
• Inflammation of the lung, joint, gut, skin and vasculature is covered, together with its links to cancer and to metabolic disease.肺、关节、肠道、皮肤与血管的炎症，连同其与癌症及代谢疾病的关联，均在收稿范围。
• Immunometabolism and inflammatory biomarkers attract increasing submissions, reflecting the journal's move towards mechanism-guided therapy.免疫代谢与炎症生物标志物吸引越来越多的投稿，反映期刊向机制导向治疗靠拢。
• Clinical studies must report ethics approval and informed consent, and work unrelated to inflammatory mechanisms is not considered.临床研究须报告伦理批准与知情同意，与炎症机制无关的研究不予考虑。

History

• The journal was launched in 2004 as an open access title from BioMed Central, and volume 1 used article numbers from the outset.本刊于 2004 年由（BioMed Central）以开放获取形式创办，首卷即采用文章编号。
• As a BioMed Central title it appeared online only from the start, without a print edition or issue-based pagination.作为（BioMed Central）旗下期刊，本刊自创刊起即仅在线出版，没有纸本，也不按期分页。
• Indexing entries carry the qualifier London, which distinguishes the title from other journals using a similar name.索引条目带有伦敦限定语，用以区别其他名称相近的刊物。
• It became affiliated with the British Inflammation Research Association, which links the journal to the United Kingdom inflammation community and to industrial members.期刊与英国炎症研究协会建立隶属关系，由此连接英国炎症研究社群及产业界成员。
• The 2025 Journal Impact Factor is 5.8, against 4.1 in 2024, 6.283 in 2022 and 4.981 in 2021.2025 年期刊影响因子为 5.8，2024 年为 4.1，2022 年为 6.283，2021 年为 4.981。
• In the 2025 Journal Citation Reports it ranks 40th of 183 titles in immunology, in the first quartile.在 2025 年期刊引证报告中，本刊于免疫学类 183 种期刊中位列第 40，属第一四分位。

Editors

• Paul Kirkham, professor of cell biology at the University of Wolverhampton, is editor-in-chief and heads its respiratory disease research group.伍尔弗汉普顿大学细胞生物学教授 Paul Kirkham 任主编，并主持该校呼吸疾病研究组。
• Adriano Rossi, professor at the University of Edinburgh, is the second editor-in-chief and works on the resolution of inflammation and respiratory pharmacology.爱丁堡大学教授 Adriano Rossi 为另一位主编，研究炎症消退与呼吸药理学。
• Kirkham's research concerns oxidative and carbonyl stress in chronic obstructive pulmonary disease, fibrosis and ageing, and he is treasurer of the British Inflammation Research Association.Kirkham 研究慢性阻塞性肺疾病、纤维化与衰老中的氧化及羰基应激，并任英国炎症研究协会司库。
• Some two dozen senior editors, four associate editors and a further editorial board support the journal, drawn mainly from the United Kingdom, Italy, China and Australia.约二十余名高级编辑、四位副编辑及另设的编委会支持期刊运作，成员主要来自英国、意大利、中国与澳大利亚。
• Median time to first decision is 15 days, and manuscripts are assessed by external experts under single-blind review.初审中位时间为 15 天，稿件由外部专家以单盲方式评审。
• Authors pay an article processing charge and all content is published open access under a CC BY licence.作者支付文章处理费，全部内容以 CC BY 许可开放获取。